Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy

Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contributions to nephrology 2007-01, Vol.157, p.109-113
Hauptverfasser: Rasche, Franz Maximilian, Keller, Frieder, von Müller, Lutz, Czock, David, Lepper, Philipp M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113
container_issue
container_start_page 109
container_title Contributions to nephrology
container_volume 157
creator Rasche, Franz Maximilian
Keller, Frieder
von Müller, Lutz
Czock, David
Lepper, Philipp M.
description Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.
doi_str_mv 10.1159/000102313
format Article
fullrecord <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_pubmed_primary_17495446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17495446</sourcerecordid><originalsourceid>FETCH-LOGICAL-k195t-6d731416c020781d56c24075bf98bad0ba19792a3a32427efd5e97750dfb99303</originalsourceid><addsrcrecordid>eNqFkEtLAzEUheMLW2sX_gEZFy5H7807y1J8FIoK1vWQaTLt2E4nJh2h_95Cde3qwOHjg3MIuUK4QxTmHgAQKEN2RC4YQw3IpaLHpI9S0pwqTU_I0CjNNAihqZbilPSBAc0Fct4jw5Q-9w6gxlCtzkkPFTeCc9kn43f_1fnNtrbrbNI03aZNXQjRp1R_-2y29NGGXVZvsrfYLv7qyWKUvfiwjG2w2-XukpxVdp388DcH5OPxYTZ-zqevT5PxaJqv0IhtLp1iyFHOgYLS6IScUw5KlJXRpXVQWjTKUMsso5wqXznhjVICXFUaw4ANyPXBG7qy8a4IsW5s3BV_a_bAzQFY2bjwsfBl265S8rH2qTg8uGdu_2OK4Cr2A2thaHE</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><source>MEDLINE</source><source>Karger Book Series</source><creator>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M.</creator><contributor>Tomino Y</contributor><creatorcontrib>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M. ; Tomino Y</creatorcontrib><description>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</description><identifier>ISSN: 0302-5144</identifier><identifier>ISBN: 9783805582865</identifier><identifier>ISBN: 3805582862</identifier><identifier>EISSN: 1662-2782</identifier><identifier>EISBN: 3318014672</identifier><identifier>EISBN: 9783318014679</identifier><identifier>DOI: 10.1159/000102313</identifier><identifier>PMID: 17495446</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject><![CDATA[Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Chapter ; Cyclophosphamide - administration & dosage ; Disease Progression ; Female ; Glomerulonephritis, IGA - drug therapy ; Humans ; Immunosuppressive Agents - administration & dosage ; Male ; Middle Aged ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - analogs & derivatives ; Prospective Studies ; Pulse Therapy, Drug ; Renal Insufficiency - drug therapy ; Steroids - administration & dosage]]></subject><ispartof>Contributions to nephrology, 2007-01, Vol.157, p.109-113</ispartof><rights>2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,775,776,780,789,26059,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17495446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tomino Y</contributor><creatorcontrib>Rasche, Franz Maximilian</creatorcontrib><creatorcontrib>Keller, Frieder</creatorcontrib><creatorcontrib>von Müller, Lutz</creatorcontrib><creatorcontrib>Czock, David</creatorcontrib><creatorcontrib>Lepper, Philipp M.</creatorcontrib><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><title>Contributions to nephrology</title><addtitle>Contrib Nephrol</addtitle><description>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</subject><subject>Chapter</subject><subject>Cyclophosphamide - administration &amp; dosage</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glomerulonephritis, IGA - drug therapy</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - administration &amp; dosage</subject><subject>Mycophenolic Acid - analogs &amp; derivatives</subject><subject>Prospective Studies</subject><subject>Pulse Therapy, Drug</subject><subject>Renal Insufficiency - drug therapy</subject><subject>Steroids - administration &amp; dosage</subject><issn>0302-5144</issn><issn>1662-2782</issn><isbn>9783805582865</isbn><isbn>3805582862</isbn><isbn>3318014672</isbn><isbn>9783318014679</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLAzEUheMLW2sX_gEZFy5H7807y1J8FIoK1vWQaTLt2E4nJh2h_95Cde3qwOHjg3MIuUK4QxTmHgAQKEN2RC4YQw3IpaLHpI9S0pwqTU_I0CjNNAihqZbilPSBAc0Fct4jw5Q-9w6gxlCtzkkPFTeCc9kn43f_1fnNtrbrbNI03aZNXQjRp1R_-2y29NGGXVZvsrfYLv7qyWKUvfiwjG2w2-XukpxVdp388DcH5OPxYTZ-zqevT5PxaJqv0IhtLp1iyFHOgYLS6IScUw5KlJXRpXVQWjTKUMsso5wqXznhjVICXFUaw4ANyPXBG7qy8a4IsW5s3BV_a_bAzQFY2bjwsfBl265S8rH2qTg8uGdu_2OK4Cr2A2thaHE</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Rasche, Franz Maximilian</creator><creator>Keller, Frieder</creator><creator>von Müller, Lutz</creator><creator>Czock, David</creator><creator>Lepper, Philipp M.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20070101</creationdate><title>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</title><author>Rasche, Franz Maximilian ; Keller, Frieder ; von Müller, Lutz ; Czock, David ; Lepper, Philipp M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-k195t-6d731416c020781d56c24075bf98bad0ba19792a3a32427efd5e97750dfb99303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration &amp; dosage</topic><topic>Chapter</topic><topic>Cyclophosphamide - administration &amp; dosage</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glomerulonephritis, IGA - drug therapy</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - administration &amp; dosage</topic><topic>Mycophenolic Acid - analogs &amp; derivatives</topic><topic>Prospective Studies</topic><topic>Pulse Therapy, Drug</topic><topic>Renal Insufficiency - drug therapy</topic><topic>Steroids - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rasche, Franz Maximilian</creatorcontrib><creatorcontrib>Keller, Frieder</creatorcontrib><creatorcontrib>von Müller, Lutz</creatorcontrib><creatorcontrib>Czock, David</creatorcontrib><creatorcontrib>Lepper, Philipp M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Contributions to nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rasche, Franz Maximilian</au><au>Keller, Frieder</au><au>von Müller, Lutz</au><au>Czock, David</au><au>Lepper, Philipp M.</au><au>Tomino Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy</atitle><jtitle>Contributions to nephrology</jtitle><addtitle>Contrib Nephrol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>157</volume><spage>109</spage><epage>113</epage><pages>109-113</pages><issn>0302-5144</issn><eissn>1662-2782</eissn><isbn>9783805582865</isbn><isbn>3805582862</isbn><eisbn>3318014672</eisbn><eisbn>9783318014679</eisbn><abstract>Backgrounds: Cyclophosphamide and high-dose steroids have been used as limited induction therapy in progressive IgA nephropathy (IgAN) to reduce the loss of renal function and proteinuria. We evaluated the effect of cyclophosphamide pulses (CyP) and mycophenolic acid (MPA) as sequential therapy on renal function in patients with progressive IgAN. Methods: Twenty patients with progressive IgAN and advanced renal failure (median GFR 22 ml/min per 1.73m2) and further disease activity (▿GFR -0.8 ml/min per month) after cyclophosphamide (CyP; n = 18) or steroid pulse therapy (n = 2) were treated with mycophenolate mofetil 1 g per day for a median of 27 months. Results: The monthly loss of renal function was significantly reduced in linear regression analysis from -2.4 ml/min before CyP to -0.12 ml/min with CyP/MPA (p = 0.0009). Estimated renal survival time was significantly prolonged by a median of 65 months (p = 0.0014). Proteinuria decreased significantly from 1.7 to 0.4 g/l during MPA treatment (p = 0.015). In Cox regression analysis, only proteinuria 1.0g/l was an independent risk factor for doubling of creatinine during CyP/MPA treatment (p = 0.03). Conclusion: A sequential therapy with CyP/MPA may arrest or slow down the loss of renal function and reduces proteinuria even in patients who passed the so called ‘point of no return’ with progressive IgAN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17495446</pmid><doi>10.1159/000102313</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-5144
ispartof Contributions to nephrology, 2007-01, Vol.157, p.109-113
issn 0302-5144
1662-2782
language eng
recordid cdi_pubmed_primary_17495446
source MEDLINE; Karger Book Series
subjects Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Chapter
Cyclophosphamide - administration & dosage
Disease Progression
Female
Glomerulonephritis, IGA - drug therapy
Humans
Immunosuppressive Agents - administration & dosage
Male
Middle Aged
Mycophenolic Acid - administration & dosage
Mycophenolic Acid - analogs & derivatives
Prospective Studies
Pulse Therapy, Drug
Renal Insufficiency - drug therapy
Steroids - administration & dosage
title Sequential Immunosuppressive Therapy in Progressive IgA Nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A05%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20Immunosuppressive%20Therapy%20in%20Progressive%20IgA%20Nephropathy&rft.jtitle=Contributions%20to%20nephrology&rft.au=Rasche,%20Franz%20Maximilian&rft.date=2007-01-01&rft.volume=157&rft.spage=109&rft.epage=113&rft.pages=109-113&rft.issn=0302-5144&rft.eissn=1662-2782&rft.isbn=9783805582865&rft.isbn_list=3805582862&rft_id=info:doi/10.1159/000102313&rft_dat=%3Cpubmed_karge%3E17495446%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=3318014672&rft.eisbn_list=9783318014679&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17495446&rfr_iscdi=true